Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Cash Flows

v3.5.0.2
Condensed Consolidated Interim Statements of Cash Flows - USD ($)
6 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Operating activities    
Net (loss) income for the period $ (1,593,226) $ 827,503
Adjustment for items not affecting cash    
Depreciation 33,753 32,480
Interest expense 10,031 0
Share- based compensation expense 424,090 1,324,282
Shares issued for services 59,500 0
Change in fair value of warrant derivative liability (1,739,047) (4,409,410)
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities (2,804,899) (2,225,145)
Changes in non-cash working capital items    
Accounts receivable (87,402) 0
Prepaid expenses and other receivables 91,430 30,460
Due from related parties (63) 1,933
Inventories (191,548) (78,071)
Accounts payable (696,874) (214,034)
Accrued liabilities (424,009) 0
Customer deposits 41,800 0
Lease payable (1,151) 0
Deferred revenue 108,482 0
Net cash used in operating activities (3,964,234) (2,484,857)
Investing activities    
Acquisition of equipment (6,848) (30,273)
Provision of a loan receivable 0 (303,760)
Net cash used in investing activity (6,848) (334,033)
Financing activities    
Proceeds from issuance of shares, net of issue costs 0 4,552,409
Cash acquired on acquisition 266,635 0
Net cash provided by financing activity 266,635 4,552,409
Effects of foreign currency exchange rate changes
Net (decrease) increase in cash and cash equivalents for the period (3,704,447) 1,733,519
Cash and cash equivalents, beginning of period 5,381,757 6,125,108
Cash and cash equivalents, end of period 1,677,310 $ 7,858,627
Assets acquired and liabilities assumed:    
Current assets, including cash acquired of $266,635 478,843  
Equipment 59,749  
Intangible assets and goodwill 27,888,979  
Accounts payable (241,299)  
Accrued liabilities (361,029)  
Customer deposits (86,487)  
Demand notes payable (324,894)  
Promissory notes payable (217,808)  
Bionik advance (1,436,164)  
Non-cash consideration $ 25,759,890